百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

First dual stem cell therapy brings new hope for cardiac repair

Donna Wong

 

190910-1_research_0.jpg
Dr Ban Ki-won (middle) and his research team at CityU.

 

A research team featuring an expert from City University of Hong Kong (CityU) has developed a novel dual approach for the first time for concurrently rejuvenating both the cardiac muscle and vasculature of the heart by utilising two types of stem cells. The results give hope for a new treatment for repairing myocardial infarction (MI) heart. 

  190910-2_research_1.jpg
These are the specimens of rats’ hearts used in the research.

 

Dr Ban Ki-won, Assistant Professor of the Department of Biomedical Sciences and his research team, including researchers from Konkuk University, The Catholic University of Korea, Pohang University of Science and Technology and T&R Biofab in South Korea, have conducted the first study of two distinct stem cell effects for cardiac repair. The two major types of stem cells employed are human bone marrow derived mesenchymal stem cells (hMSCs) and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). The research findings have been published in Nature Communications in a paper titled “Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction”. 

“Both cardiac muscles and vasculatures are severely damaged following MI, and so the therapeutic strategies should focus on comprehensive repair of both at the same time. But the current strategies only focus on either one,” Dr Ban said. 

Dr Ban said that, with limited therapeutic options for severe MI and advanced heart failure, a heart transplant was the last resort. However, such an operation is very risky, costly and subject to limited supply of suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

190910-3_research_4.jpg
Representative immunostaining images showing hiPSC-CM-GFP (green) and MYH6/7 gene (red) when hiPSC-CMs were injected in MI hearts.

 

In the study, the hiPSC-CMs were injected directly into the border zone of the rat's heart, while the hMSCs-loaded patch was implanted on top of the infarct area, like a bandage. The results showed that this dual approach led to a significant improvement of cardiac function and an enhancement of vessel formation on a MI heart. 

“We believe this novel dual approach can potentially provide translational and clinical benefit to the field of cardiac regeneration. Based on the same principle, the protocol may also be utilised for repairing other organs including the brain, liver and pancreas in which multiple types of stem cells co-exist,” Dr Ban added. 

The research team is working on follow-up studies in larger animal models such as pigs. The patent application for this research result has been submitted.

The first co-authors of the paper are Dr Park Soon-jung from Konkuk University School of Medicine, Dr Kim Ri-youn and PhD student Lee Sung-hun from CityU and PhD student Park Bong-woo from The Catholic University of Korea.

 

 

YOU MAY BE INTERESTED

Contact Information

Communications and Institutional Research Office

Back to top
百家乐官网庄闲分布概率| 百家乐赌台| 博彩百家乐心得| 正品百家乐地址| 九头鸟棋牌游戏中心| 奇博国际娱乐| 百家乐官网园云鼎赌场娱乐网规则 | 新百家乐官网的玩法技巧和规则| 百家乐开发软件| 大发麻将| 环球百家乐官网的玩法技巧和规则 | 网上百家乐哪家较安全| 新奥博娱乐城体育投注| 超级百家乐官网2龙虎斗| 百家乐路单破解软件| 大发扑克官网| 网上百家乐官网是不是真的| 中华百家乐的玩法技巧和规则 | 线上百家乐攻略| 澳门金沙娱乐场| 做生意摆放风水| 棋牌新教室| 博九网百家乐现金网| 六合彩报码| 百家乐扑克多少张| 玩百家乐官网的玩法技巧和规则 | 澳门百家乐娱乐城送体验金| 广西| 百家乐官网的薇笑打法| 威尼斯人娱乐网开户| 百家乐官网象棋玩法| 大发888娱乐游戏下载 官方网| 百家乐官网下| 大发888扑克场| 百家乐网上投注文章| 百家乐官网翻天qvod粤语| 百家乐筹码套装100片| 百家乐官网现金网平台排名| 百家乐扫描技术| 百家乐官网tt娱乐场| 明升国际网|